Goldman Sachs Group Inc. reduced its holdings in shares of CryoLife, Inc. (NYSE:CRY) by 52.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 21,236 shares of the medical equipment provider’s stock after selling 23,588 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.06% of CryoLife worth $424,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of the stock. Voya Investment Management LLC lifted its holdings in CryoLife by 9.6% during the second quarter. Voya Investment Management LLC now owns 17,493 shares of the medical equipment provider’s stock worth $349,000 after acquiring an additional 1,534 shares during the period. B. Riley Financial Inc. bought a new stake in CryoLife during the second quarter worth $579,000. Dimensional Fund Advisors LP lifted its holdings in CryoLife by 6.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,960,221 shares of the medical equipment provider’s stock worth $39,107,000 after acquiring an additional 110,973 shares during the period. Parametric Portfolio Associates LLC lifted its holdings in CryoLife by 70.4% during the second quarter. Parametric Portfolio Associates LLC now owns 127,230 shares of the medical equipment provider’s stock worth $2,538,000 after acquiring an additional 52,584 shares during the period. Finally, Connors Investor Services Inc. lifted its holdings in CryoLife by 0.9% during the second quarter. Connors Investor Services Inc. now owns 108,907 shares of the medical equipment provider’s stock worth $2,173,000 after acquiring an additional 932 shares during the period. Institutional investors and hedge funds own 70.34% of the company’s stock.
CryoLife, Inc. (NYSE:CRY) opened at $19.35 on Wednesday. The firm has a market capitalization of $637.37, a price-to-earnings ratio of 46.46 and a beta of 0.82. CryoLife, Inc. has a 52-week low of $14.02 and a 52-week high of $24.00. The company has a debt-to-equity ratio of 0.29, a current ratio of 5.96 and a quick ratio of 4.90.
CryoLife (NYSE:CRY) last announced its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.08. CryoLife had a return on equity of 6.43% and a net margin of 5.28%. The company had revenue of $44.00 million during the quarter, compared to analysts’ expectations of $44.60 million. During the same period in the previous year, the business earned $0.13 earnings per share. The firm’s quarterly revenue was down 2.9% compared to the same quarter last year. analysts anticipate that CryoLife, Inc. will post 0.28 EPS for the current year.
Several analysts have issued reports on the company. Canaccord Genuity restated a “buy” rating and issued a $25.00 target price on shares of CryoLife in a research note on Monday, October 9th. Lake Street Capital boosted their target price on CryoLife to $26.00 and gave the company a “buy” rating in a research note on Wednesday, October 11th. Zacks Investment Research lowered CryoLife from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. BidaskClub lowered CryoLife from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Finally, TheStreet lowered CryoLife from a “b” rating to a “c+” rating in a research note on Monday, October 30th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. CryoLife presently has a consensus rating of “Hold” and an average target price of $23.63.
In other news, Director James Benson sold 2,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $22.80, for a total value of $45,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO David Ashley Lee sold 33,190 shares of the company’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $19.00, for a total value of $630,610.00. Following the completion of the transaction, the chief financial officer now owns 324,339 shares of the company’s stock, valued at $6,162,441. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 209,240 shares of company stock valued at $4,495,465. 6.00% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Week Herald and is the property of of Week Herald. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://weekherald.com/2017/11/15/cryolife-inc-cry-position-reduced-by-goldman-sachs-group-inc.html.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoLife, Inc. (NYSE:CRY).
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.